WCN25-191 MULTI-OMICS ANALYSIS REVEALS PLASMA BIOMARKER CANDIDATES FOR CALCIFIC UREMIC ARTERIOLOPATHY PATIENTS TREATED WITH HUMAN AMNION-DERIVED MESENCHYMAL STEM CELLS

than two thirds of participants aged either 18-30 or 31-45 years.Individuals will have 4 visits at eight-month intervals.Biological samples and environmental samples are collected following standard procedures.REDCap questionnaires capture data on family structure, demographics, medical history, recent medical visits, medication use, occupational and environmental exposures, diet, and alcohol and tobacco use.Serum, plasma, whole blood, and urine will be collected, locally processed, and shipped to a biorepository in the United States for CLIA-certified laboratory assays, including IDMS-traceable creatinine assays to establish baseline eGFR, kidney function biomarkers, pathogens, trace elements, untargeted metabolomics, and genetic assays.Environmental samples will be collected from a subset of study participants analyzed for trace elements, agrochemicals, and burning exposures.The statistical plan aims to identify risk factors for CKDu, including complex relationships and interactions, while controlling for confounders.Associations between individual risk factors and each of the study outcomes will be estimated using models that include a single risk factor as the exposure, with appropriate controls, as well as mixture models. Results: Conclusions:Implementing a prospective cohort study across multiple sites requires the involvement of investigators across diverse areas of expertise and local stakeholders.The findings will help identify exposures to address through targeted workplace or community interventions.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.